Risk Factors for HCV

HCV Info Fact

24 August 2003

The risk factors for Hepatitis C Virus infection are:

  1. Intravenous drug use- Current or remote intravenous drug use accounts for 50% of new cases of HVC; 50% to 60% infected with HCV within 3 months of initiation of injection behavior
  2. Intranasal cocaine- Risk factor suggested by epidemiologic evidence
  3. Tattooing – Remains controversial as a risk factor
  4. Health care workers – Risk for HCV infection is fourfold that of blood donors; for needlestick injury, seroconversion rate is approximately 2%
  5. Transfusion of blood products – With modern screening. Risk for HCV transmission is estimated at 0.01% to .0.001 % per unit transfused
  6. Hemodialysis -U.S patients receiving hemodialysis have 10% to 20% prevalence of chronic HCV infection
  7. Sexual transmission- Estimated risk is 1% to 3% over lifetime of a monogamous relationship; barrier methods deed unnecessary in monogamous couples
  8. Vertical transmission- Estimated risk is approximately 5% per exposure; testing of infants not recommended before 1 year of age; breast feeding considered low risk

Chronic hepatitis C virus infection is common and often asymptomatic. Antibodies against HCV are a highly sensitive marker of infection. Molecular testing for HCV is used to confirm a positive result on antibody testing and to provide prognostic information for treatment; however, quantitative HCV RNA does not correlate with disease severity or risk for progression. Chronic HCV infection is most frequently associated with remote or current intravenous drug use and blood transfusion before 1992, although as many as 20%of infected patients have no identifiable risk factor. In an estimated 15% to 20% of persons infected with HCV, the infection progresses to cirrhosis; alcohol intake is an important factor in this progression. Most specialists prefer to include an examination of a liver biopsy in the management of patients with chronic HCV infection to aid prognostic and treatment decisions. The current standard of pharmacologic treatment of chronic HCV is weekly subcutaneous peginterferon in combination with daily oral ribavirin, which results in sustained virologic response in approximately 55% of chronically infected patients. Side effects of interferon therapy include myalgias, fever, nausea, irritability, and depression. The primary care physician and gastroentrologist serve a vital role in identifying patients with chronic HCV infection, educating patients with chronic HCV infection, educating patients about risk factors for transmission, advising patients about the avoidance of alcohol, and aiding patients in making treatment decisions.

Info Facts are prepared by the HCV Committee and under the direction of Dr. Kishore.

Similar Posts

  • Publication Index

    Admin 03/18/2022

    FOR IMMEDIATE RELEASE: October 9, 2002 NIDA Contact: Michelle Person 301-443-6245 SAMHSA Contact: Leah Young 301-443-8956 NIDA Research and SAMHSA Physician Training Combine to Put Care for Opiate Dependence in Hands of Family Doctor. Buprenorphine, a new medication developed through more than a decade of research supported by the National Institute on Drug Abuse (NIDA),…

  • National Alliance for Medication Assisted Recovery 435 Second Avenue New York, NY 10010      

    Admin 06/03/2023

    Membership Application Name:   _______________________________________________________   Mr. ___  Ms. ___  Dr. ___ Organization:  __________________________________________________________________________ Title:  _____________________________________________  Degree(s):  ________________________ Address:  _____________________________________________________________________________ Address:  _____________________________________________________________________________ City:   __________________________________   State:   ____________   Postal Code:   _____________ Email:  ______________________________________  Country:   ________________________________ Home Phone: (____)___________________________   Work Phone:  (____)_______________________ Alternate Phone:  (____)________________________   Fax:  (____)______________________________ If you have email may we send you bulletin alerts electronically. (This will get bulletin alerts to you quicker than usual mail)   Yes  _____   No _____ Types of Membership $_______ Individual Membership   Dues: $25 a…

  • Conferences and Events

    Admin 02/17/2023

    2009 American Association for the Treatment of Opioid Dependence April 25 – 29, 2009 New York The next AATOD National Conference will be convening on April 25 – 29, 2009 at the Hilton New York in New York, New York . AATOD produces national conferences on an 18-month cycle. These conferences have been convening since…

  • Category: Patient Rights

    Admin 05/02/2022

    DOJ publishes guidance on Opioid Use Disorder and the Americans with Disabilities Act April 15, 2022 “The opioid crisis poses an extraordinary challenge to communities throughout our country. The Department of Justice (the Department) has responded with a comprehensive approach prioritizing prevention, enforcement, and treatment. This includes enforcing the Americans with Disabilities Act (Ada), which…

  • Recovery Advocates Sharpen Their Skills By Bob Curley

    Admin 04/15/2022

    Feature Story Join Together Online June 3, 2004. Seeking to empower grassroots advocates for addiction recovery, the group Faces and Voices of Recovery (FAVOR) recently held the first in a planned series of national advocacy-training sessions in Braintree, Mass. Cosponsored by a pair of regional advocacy groups, the New England Alliance of Addiction Recovery Communities…